Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
How does residual DCIS after neoadjuvant chemotherapy impact prognosis if there is a CR of the invasive disease?
Answer from: Radiation Oncologist at Community Practice
The majority of studies suggest residual DCIS has the same outcome as pCR with no invasive disease and thus is still treated as pCR in practice.
Sign in or Register to read more
17488
Related Questions
When do you consider the addition of concurrent pembrolizumab to breast irradiation?
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
When utilizing hypofractionated radiotherapy in the post mastectomy setting, are the nodal regions dose painted to a different dose or the same dose as the chest wall/reconstructed breast?
In patients with HER-2 positive breast cancer on pertuzumab/trastuzumab with newly developed asymptomatic brain metastases only, do you wait 3 weeks after administration of the targeted therapy to deliver SRS?
Would you offer PMRT when the only indication is a focally positive margin?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
Would you consider once weekly radiation with a simultaneous integrated boost for a patient with node negative breast cancer with a positive margin for whom reexcision is not an option?
How would you approach radiation for an elderly patient with pT2N1 TNBC s/p MRM and ALND who refused chemo-immunotherapy?
When using FAST Forward, how important is it for the treatment to be delivered Monday through Friday in one week as opposed to spanning a weekend?
Would you consider radiation omission for a patient with a Stage I breast cancer with an elevated Oncotype Dx?